Business
How $594B in Precision Tech is Cracking the Metastatic Cancer Code
How $594B in Precision Tech is Cracking the Metastatic Cancer Code Canada NewsWire ...
About this update from Briacell Therapeutics Corp
[{"type":"text","content":"\n\n\nHow $594B in Precision Tech is Cracking the Metastatic Cancer Code\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\nCanada NewsWire\n\n\nIssued on behalf of Oncolytics Biotech Inc. \nUSANewsGroup.com News Commentary\nVANCOUVER, BC, Jan. 7, 2026 /CNW/ -- The global cancer drugs market is surging toward $594.3 billion by 2035 as high-tech immunotherapies begin to replace traditional chemotherapy[1]. With response rates now exceeding 90% in some previously untreatable blood cancers, these platforms are demonstrating a unique ability to reactivate a patient's own immune system to fight back[2]. This fundamental shift toward \"reprogramming\" the body's defenses drives the investment case for Oncolytics Biotech Inc. (NASDAQ: ONCY), BriaCell Therapeutics Corp. (NASDAQ: BCTX) (TSX: BCT), Greenwich LifeSciences, Inc. (NASDAQ: GLSI), Citius Oncology (NASDAQ: CTOR), and Kazia Therapeutics Limited (NASDAQ: KZIA). \n \n\n \nWith the metastatic cancer treatment market already valued at $84.66 billion, precision-guided therapies now command a dominant 54.51% market share as they displace toxic legacy regimens[3]. As capital flows into these novel modalities, the industry is entering a new era where metastatic spread is no longer an insurmountable barrier, but a prime target for smart, targeted activation. \nClinical-stage biotech company Oncolytics Biotech Inc. (NASDAQ: ONCY) is well on its way in developing pelareorep, an investigational immunotherapy designed to activate the immune system against cancer. \nClosing out the company's 2025, Oncolytics announced exciting efficacy data showing pelareorep achieved a 33% objective response rate in second-line KRAS-mutant microsatellite-stable metastatic colorectal cancer patients when combined with standard chemotherapy. This triples the historical 6-11% response rate for chemotherapy alone in this difficult-to-treat population, addressing a colorectal cancer market projected to reach $20 billion by 2033. \nEqually compelling anal cancer results put out in late October showed a 30% response rate i...